Complete Filing Data
AKANDA CORP. reported Issue Of Equity of $12.93 million for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean AKANDA CORP. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Profit Loss | -$4.1M | -$32.3M | -$11.7M | -$8.1M | -$2.3M | -$1.4M |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$101.2K | -$39.4K | -$1.4M | $110.0K | $150.6K | -$42.6K |
| Comprehensive Income | -$4.2M | -$32.3M | -$13.1M | -$8.0M | -$2.1M | -$1.4M |
| General And Administrative Expense | $1.3M | $323.3K | $3.4M | $170.9K | $229.7K | $179.7K |
| Adjustments For Interest Expense | $100.1K | $237.3K | $211.0K | $1.1M | ||
| Profit Loss From Operating Activities | -$4.4M | -$3.7M | -$20.2M | -$2.6M | -$1.7M | -$901.2K |
| Profit Loss From Continuing Operations | -$3.3M | -$3.7M | -$8.2M | -$2.5M | ||
| Profit Loss From Discontinued Operations | -$827.6K | -$28.6M | -$3.4M | -$5.7M | ||
| Cost Of Sales | $628.3K | $364.3K | $566.3K | $43.0K | $1.8K | |
| Gross Profit | $208.4K | $59.3K | $3.3M | -$1.6K | -$58.2K | |
| Operating Expense Excluding Cost Of Sales | $23.4M | $25.7M | $1.6M | $901.2K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Issue Of Equity | $12.9M | $314.4K | $6.6M | $385.0K | $1.5K | $156.00 | |
| Cash And Cash Equivalents | $3.8M | $93.9K | $255.8K | $3.5M | $13.5K | $819.6K | $24.1K |
| Cash Flows From Used In Investing Activities | -$1.0M | $24.9K | -$4.2M | -$576.5K | -$432.2K | -$692.8K | |
| Cash Flows From Used In Financing Activities | $9.0M | $1.5M | $14.1M | $11.2M | $1.0M | $2.1M | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $2.1M | $1.5K | $310.9K | $576.5K | $439.1K | $670.3K | |
| Cash Flows From Used In Operating Activities | -$4.0M | -$1.5M | -$11.5M | -$6.6M | |||
| Property Plant And Equipment | $2.3M | $2.5M | $12.2M | $1.9M | $1.6M | ||
| Adjustments Of Gain On Settlement On Debt | $27.6K | $113.0K | $67.1K | ||||
| Trade And Other Current Payables | $3.0M | $6.0M | $7.1M | $680.3K | $183.9K | ||
| Retained Earnings | -$57.5M | -$53.4M | -$21.1M | -$13.3M | -$5.2M | ||
| Noncurrent Assets | $2.9M | $7.0M | $35.2M | $4.1M | $4.1M | ||
| Liabilities | $3.6M | $12.7M | $12.1M | $10.2M | $9.3M | ||
| Equity And Liabilities | $7.9M | $8.8M | $39.0M | $8.0M | $4.3M | ||
| Current Liabilities | $3.6M | $10.2M | $9.3M | $8.3M | $2.7M | ||
| Current Assets | $5.1M | $1.8M | $3.8M | $4.0M | $127.6K | ||
| Assets | $7.9M | $8.8M | $39.0M | $8.0M | $4.3M | ||
| Accumulated Other Comprehensive Income | -$1.6M | -$1.5M | -$1.5M | $218.1K | $108.1K | ||
| Rightofuse Assets | $122.0K | $324.1K | $1.9M | $2.2M | |||
| Intangible Assets Other Than Goodwill | $15.8K | $3.8M | $22.2M | $259.1K | $321.4K | ||
| Trade And Other Current Receivables | $370.5K | $284.5K | $1.2M | $242.4K | |||
| Current Lease Liabilities | $135.3K | $214.1K | $439.7K | $284.0K | |||
| Noncurrent Liabilities | $2.5M | $2.7M | $2.0M | $6.6M | |||
| Adjustments For Increase Decrease In Other Current Liabilities | -$42.9K | $91.4K | $66.0K | $496.4K | |||
| Gross Loss Profit Before Loss On Change In Fair Value Biological Assets | $251.5K | $2.1M | -$1.6K | $253.00 | |||
| Cash And Cash Equivalents Including Cash Held In Trust | $255.8K | $3.5M | $13.5K | ||||
| Noncurrent Lease Liabilities | $116.8K | $2.0M | $2.6M | ||||
| Gains Losses On Fair Value Adjustment Biological Assets | -$140.1K | $1.2M | -$713.1K | -$58.4K | |||
| Adjustments For Increase Decrease In Trade And Other Payables | -$733.4K | $1.5M | $2.9M | ||||
| Adjustments For Decrease Increase In Trade And Other Receivables | -$254.7K | $973.4K | -$591.1K | ||||
| Trade And Other Current Payables To Related Parties | $302.2K | $2.3M | $679.6K | ||||
| Gains Losses On Financial Assets At Fair Value Through Profit Or Loss Mandatorily Measured At Fair Value | -$264.7K | -$516.3K | |||||
| Adjustments For Decrease Increase In Financial Assets Held For Trading | $264.7K | $516.3K | |||||
| Adjustments For Increase Decrease In Trade Account Payable | $2.9M | $140.9K | $42.3K | ||||
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | -$105.2K | -$739.9K | |||||
| Gain On Change In Fair Value Of Biological Assets1 | -$140.1K | $1.2M | -$713.1K | -$58.4K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | $4.0M | $10.9K | -$1.5M | $4.1M | -$751.2K | $781.2K |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$244.9K | -$172.8K | -$1.7M | -$620.3K | -$54.9K | $14.2K |
| Proceeds From Borrowings Classified As Financing Activities | $65.3K | $742.6K | $501.2K | $6.7M | $1.2M | $2.1M |
| Payments Of Lease Liabilities Classified As Financing Activities | $300.0K | $60.0K | $646.0K | $497.5K | ||
| Proceeds From Issuing Shares | 10.8M | 278.5K | 5.1M | 1.5K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Weighted Average Shares | 1.0M | 56.3K | 3.0M | 16.2M | 13.1M | 13.1M |
| Diluted Earnings Loss Per Share | $-3.93 | $-573.11 | $-3.86 | $-0.50 | $-0.18 | $-0.11 |
| Basic Earnings Loss Per Share | $-3.93 | $-573.11 | $-3.86 | $-0.50 | $-0.18 | $-0.11 |
| Diluted Earnings Loss Per Share From Continuing Operations | $-3.14 | $-65.92 | $-2.75 | $-0.15 | ||
| Basic Earnings Loss Per Share From Continuing Operations | $-3.14 | $-65.92 | $-2.75 | $-0.15 | ||
| Weighted Average Share Price2019 | 25.00 | 0.01 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Adjustments For Depreciation And Amortisation Expense | $141.1K | $209.2K | $3.8M | $309.0K | $248.7K | $198.8K |
| Adjustments For Decrease Increase In Prepaid Expenses | -$285.6K | $64.6K | -$709.1K | -$129.0K | -$113.2K | -$310.00 |
| Professional Fees Expense | $2.7M | $2.7M | $7.8M | $1.2M | $702.0K | $365.6K |
| Finance Costs | $100.1K | $121.4K | $115.3K | $10.5K | $645.2K | $493.8K |
| Employee Benefits Expense | $495.7K | $486.5K | $6.6M | $1.2M | $374.9K | $100.3K |
| Depreciation And Amortisation Expense | $141.1K | $209.2K | $3.6M | $478.00 | $248.7K | $198.8K |
| Other Income | $238.6K | $7.1K | $659.00 | $54.00 | $108.00 | |
| Repayments Of Borrowings Classified As Financing Activities | $104.9K | $766.2K | $649.7K | $137.8K | ||
| Other Reserves | $24.4K | $21.1K | $21.1K | $3.6M | $21.1K | |
| Finance Income | $6.5K | $39.00 | $886.00 | $90.00 | $10.2K | $401.00 |
| Current Prepayments | $391.6K | $140.6K | $199.5K | $242.5K | $113.5K | |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -$133.0K | $41.7K | -$256.4K | $106.8K | ||
| Issued Capital | $63.3M | $51.0M | $49.4M | $7.3M | $1.6K | |
| Shortterm Borrowings | $352.8K | $1.4M | $936.8K | |||
| Adjustments For Decrease Increase In Inventories | $366.2K | $482.7K | $501.7K | -$712.5K | -$611.00 | |
| Operating Expense | $4.6M | $3.7M | $23.4M | |||
| Finance Income Cost | $1.1M | -$53.6K | $11.9M | |||
| Inventories | $1.3M | $1.1M | $611.00 | |||
| Adjustments For Fair Value Gains Losses | $1.5M | $839.9K | $2.5M | |||
| Longterm Borrowings | $2.5M | $2.6M |
Most recent annual filing with the SEC: April 30, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.